Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2562856 | 0.83 | HSD17B10 (0.61) | HSD17B10MAPTALDH1A1GAAKDM4E | |
| SCHEMBL14097991 | 0.80 | HSD17B10 (0.57) | HSD17B10MAPTALDH1A1GAATDP1 | |
| SCHEMBL2562283 | 0.80 | HSD17B10 (0.57) | HSD17B10MTNR1BALDH1A1KDM4EMEN1 | |
| SCHEMBL2369905 | 0.79 | KDM4E (0.56) | HSD17B10MTNR1BMAPTALDH1A1GAA | |
| SCHEMBL504029 | 0.78 | HSD17B10 (1.00) | HSD17B10MTNR1BMAPTGAAKDM4E | |
| SCHEMBL30512021 | 0.78 | HSD17B10 (1.00) | HSD17B10MTNR1BMAPTGAAKDM4E | |
| SCHEMBL2560429 | 0.77 | HSD17B10 (0.51) | HSD17B10NR3C1 | |
| Hydrochloric Acid SCHEMBL2527402 | 0.76 | HSD17B10 (0.97) | HSD17B10MTNR1BMAPTGAAKDM4E | |
| SCHEMBL5743085 | 0.76 | HSD17B10 (0.68) | HSD17B10MTNR1BMAPTKDM4EAKR1C3 | |
| SCHEMBL154368 | 0.76 | HSD17B10 (0.68) | HSD17B10MAPTALDH1A1GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130338177-A1 | Spiro-Amino-Imidazolone and Spiro-Amino-Dihydro-Pyrimidinone Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2643325-A1 | SPIRO-AMINO-IMIDAZOLONE AND SPIRO-AMINO-DIHYDRO-PYRIMIDINONE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012071279-A1 | SPIRO-AMINO-IMIDAZOLONE AND SPIRO-AMINO-DIHYDRO-PYRIMIDINONE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338177-A1 | Spiro-Amino-Imidazolone and Spiro-Amino-Dihydro-Pyrimidinone Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | HSD17B10 1196/4885MTNR1B 2218/4885CXCL8 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.